Citation: | PENG Yuanzhou, HA Yongting, LI Wenhao, HUANG Fang, XIE Xu, CHENG Jinquan, WU Yu, ZHANG Yanwei. Effect of different immunization schedules on diphtheria antibody level among preschool children in Shenzhen[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2023, 44(3): 415-418. doi: 10.16835/j.cnki.1000-9817.2023.03.022 |
[1] |
WHO. Diphtheria vaccine: WHO position paper, August 2017-recommendations[J]. Vaccine, 2018, 36(2): 199-201. doi: 10.1016/j.vaccine.2017.08.024
|
[2] |
WHO. Global Vaccine Action Plan 2011-2020[J]. Geneva: WHO, 2012, 31(Suppl 2): B5-B31.
|
[3] |
TRUELOVE S A, KEEGAN L T, MOSS W J, et al. Clinical and epidemiological aspects of diphtheria: a systematic review and pooled analysis[J]. Clin Infect Dis, 2020, 71(1): 89-97. doi: 10.1093/cid/ciz808
|
[4] |
王华庆, 郭欣, 陈丽, 等. 国家计划免疫综合审评县2004年农村儿童白喉免疫水平与百白破疫苗接种率调查[J]. 中华流行病学杂志, 2007, 28(5): 433-436. doi: 10.3760/j.issn:0254-6450.2007.05.005
WANG H Q, GUO X, CHEN L, et al. Survey on diphtheria immunity level and diphtheria diphtheria vaccine coverage rate of rural children in the comprehensive evaluation counties of national planned immunization in 2004[J]. Chin J Epidemiol, 2007, 28(5): 433-436. (in Chinese) doi: 10.3760/j.issn:0254-6450.2007.05.005
|
[5] |
梁亮, 马宇燕, 韦敬航, 等. 广西壮族自治区2013年健康人群白喉抗体水平调查[J]. 中国疫苗和免疫, 2016, 22(2): 175-179. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201602010.htm
LIANG L, MA Y Y, WEI J H, et al. Antibody levels against diphtheria among a healthy population in Guangxi Zhuang Autonomous Region, 2013[J]. Chin J Vaccin Immun, 2016, 22(2): 175-179. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201602010.htm
|
[6] |
徐蕊, 葛为民, 杨恒丹, 等. 平顶山市2005—2019年学龄前和学龄儿童百日咳流行病学特征分析[J]. 医学动物防制, 2021, 37(10): 939-942. doi: 10.7629/yxdwfz202110006
XU R, GE W M, YANG H D, et al. Epidemiological characteristics of pertussis in kindergarten children and primary school students in Pingdingshan from 2005 to 2019[J]. J Med Pest Control, 2021, 37(10): 939-942. (in Chinese) doi: 10.7629/yxdwfz202110006
|
[7] |
麦炜桢, 康敏, 朱琦, 等. 新冠肺炎疫苗免疫原性影响因素研究进展[J]. 华南预防医学, 2022, 48(5): 568-572. https://www.cnki.com.cn/Article/CJFDTOTAL-GDWF202205011.htm
MAI W Z, KANG M, ZHU Q, et al. Research progress on influencing factors of immunogenicity of COVID-19 vaccine[J]. South Chin J Prev Med, 2022, 48(5): 568-572. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-GDWF202205011.htm
|
[8] |
国家卫生健康委员会. 国家免疫规划疫苗儿童免疫程序及说明(2021年版)[J]. 中国病毒病杂志, 2021, 11(4): 241-245. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX202104001.htm
National Health Commission of the PRC. Immunization schedules and instructions for vaccines of the national immunization program(2021 version)[J]. Chin J Viral Dis, 2021, 11(4): 241-245. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX202104001.htm
|
[9] |
CORBEL M J, DAS R G, LEI D, et al. WHO Working Group on revision of the Manual of Laboratory Methods for Testing DTP Vaccines: report of two meetings held on 20-21 July 2006 and 28-30 March 2007, Geneva, Switzerland[J]. Vaccine, 2008, 26(16): 1913-1921. doi: 10.1016/j.vaccine.2008.02.013
|
[10] |
孔江南, 刘倩, 丰达星, 等. 2020年河南省0~79岁健康人群白喉抗体水平调查[J]. 中国疫苗和免疫, 2022, 28(5): 521-524. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202205005.htm
KONG J N, LIU Q, FENG D X, et al. Diphtheria antibody levels among a 0-79-year-old healthy population of Henan Province in 2020[J]. Chin J Vaccin Immun, 2022, 28 (5): 521-524. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202205005.htm
|
[11] |
陈致飞, 张海荣, 王琴, 等. 福建省2018年0-61岁社区人群白喉抗体水平调查[J]. 中国疫苗和免疫, 2020, 26(5): 521-524. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202005008.htm
CHEN Z F, ZHANG H R, WANG Q, et al. Diphtheria antibody levels among a community-dwelling population aged 0-61 years in Fujian Province, 2018[J]. Chin J Vaccin Immun, 2020, 26(5): 521-524(in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202005008.htm
|
[12] |
耿少良, 赵鸣, 郭沙沙, 等. 2020年许昌市健康人群白喉抗体水平调查[J]. 中国疫苗和免疫, 2021, 27(5): 537-539. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202105011.htm
GENG S L, ZHAO M, GUO S S, et al. Diphtheria antibody levels and sero-prevalence among healthy people of Xuchang City in 2020[J]. Chin J Vaccin Immun, 2021, 27(5): 537-539. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202105011.htm
|
[13] |
朱琦, 刘美真, 吴承刚, 等. 2014年广东省部分地区白喉抗体水平调查[J]. 中国疫苗和免疫, 2016, 22(3): 267-270. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201603007.htm
ZHU Q, LIU M Z, WU C G, et al. Diphtheria antibody levels in selected regions of Guangdong Province, 2014[J]. Chin J Vaccin Immun, 2016, 22(3): 267-270. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201603007.htm
|
[14] |
陈霞, 唐继海, 毛雷婧, 等. 2016年安徽省部分地区健康人群白喉抗体水平监测[J]. 中国疫苗和免疫, 2018, 24(2): 207-210. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201802017.htm
CHEN X, TANG J H, MAO L J, et al. Surveillance of antibody levels against diphtheria in Anhui Province in 2016[J]. Chin J Vaccin Immun, 2018, 24(2): 207-210. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201802017.htm
|
[15] |
BRANDON D, KIMMEL M, KURIYAKOSE S O, et al. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults[J]. Vaccine, 2018, 36(42): 6325-6333. https://www.sciencedirect.com/science/article/pii/S0264410X18311800
|
[16] |
李思遥, 彭兴慧. 2016年北京市密云区白喉基础免疫效果观察[J]. 首都公共卫生, 2019, 13(2): 100-101. https://www.cnki.com.cn/Article/CJFDTOTAL-SDGW201902013.htm
LI S Y, PENG X H. Observation on the effect of diphtheria basic immunization in Miyun District of Beijing in 2016[J]. Capit J Public Health, 2019, 13(2): 100-101. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-SDGW201902013.htm
|
[17] |
POLONSKY J A, IVEY M, MAZHAR M K A, et al. Epidemiological, clinical, and public health response characteristics of a large outbreak of diphtheria among the Rohingya population in Cox's Bazar, Bangladesh, 2017 to 2019: a retrospective study[J]. PLoS Med, 2021, 18(4): e1003587.
|
[18] |
KANG J H, LEE H J, KIM K H, et al. The immunogenicity and safety of a combined DTaP-IPV//hib vaccine compared with individual DTaP-IPV and hib (PRP-T) vaccines: a randomized clinical trial in south Korean infants[J]. J Korean Med Sci, 2016, 31(9): 1383-1391.
|
[19] |
PABLO, OBANDO-PACHECO, IRENE, et al. DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age[J]. Exp Rev Vaccin, 2019, 18(11): 1115-1126.
|